摘要
目的探讨糖类抗原检测用于非小细胞肺癌(NSCLC)诊疗的临床意义。方法采用血清糖类抗原多肿瘤标志物蛋白芯片检测系统对已确诊的60例NSCLC患者的血清CA19-9、CA242、CA125和CA153水平进行检测,并与肺良性病变对照组和健康对照组进行比较。结果肺癌组血清CA19-9、CA242、CA125和CA153的阳性检出率高于肺良性病变对照组和健康对照组,且3组血清CA19-9、CA125和CA153的差异尤为显著(P<0.05)。肺腺癌患者血清CA19-9和CA125的阳性检出率高于肺鳞癌患者(P<0.05)。NSCLC患者分期越晚,4种糖类抗原的阳性检出率越高,其中CA125和CA153在Ⅰ～Ⅱ期的阳性检出率分别为38.5%和30.8%,高于CA19-9和CA242的7.7%和7.7%(P<0.05)。结论糖类抗原检测在NSCLC诊疗方面具有较好的临床应用价值,可以作为诊断、分期及病程监测等方面常规检测方法的辅助手段。
Objective To explore the clinical significance of the carbohydrate antigen detection for diagnosis and treatment in non-small cell lung cancer（NSCLC）. Methods The levels of serum CA19-9, CA242, CA125 and CA153 of 60 confirmed patients with NSCLC were measured by multiple tumor marker protein chip detection system and were compared with benign lung lesions control group and the healthy control group. Results The positive rate of serum CA19-9, CA242, CA125 and CA153 in the lung cancer group were higher than benign lung lesions control group and healthy control group, but there was particularly apparent difference in se- rum CA19-9, CA125 and CA153 （P 〈 0. 05）. The positive rates of serum CA19-9 and CA125 in the patients with lung adenocarcinoma were significantly higher than those in patients with squamous cell carcinoma（P 〈 0. 05）. The positive rates of 4 carbohydrate antigens raised with clinical stages. The positive rates of CA125 and CA153 in stageⅠ～Ⅱ were 38.5% and 30. 8%, which were higher than those of CA19-9 and CA242, with significant differences （P 〈 0. 05 ）. Conclusion The carbohydrate antigen for diagnosis and treat- ment of NSCLC has considerable clinical values, can be used as auxiliary examination to the conventional methods in detecting NSCLC.
出处
《临床肿瘤学杂志》
CAS
2013年第2期144-146,共3页
Chinese Clinical Oncology
基金
国家自然科学基金资助项目(BA11-81172503)
关键词
糖类抗原
非小细胞肺癌
蛋白芯片
Carbohydrate antigen
Non-small cell lung cancer
Protein chip
